Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Verona Pharma PLC

www.veronapharma.com

Latest From Verona Pharma PLC

Verona Foresees FDA End-Of-Phase II COPD Meeting

Verona CEO tells Scrip Phase III COPD studies for its lead asset will start next year, take up to two years to complete, leading to commercial launch “probably in 2024.”

Companies Strategy

The Many Paths To Biotech CEO

There is no single path toward becoming a CEO. The job requires many different skills, often concurrently: sharp analytical capabilities, strategic thinking, clear communication with multiple audiences, curiosity and perseverance. It demands strong leadership but also humility, and a willingness to acknowledge mistakes and knowledge gaps.

C-Suite Speaks Business Strategies

Verona Investors Gasp As Lead Asset Misses Main Endpoint In COPD Trial

Verona’s shares sank after a brief three-day Phase II trial using lead asset RPL554 in patients already maximally bronchodilated on both a LAMA and LABA missed the primary endpoint.

Clinical Trials Respiratory

Under The Radar: Potential Small Cap Takeover Targets

Looking back at the second quarter, PharmaVitae analysts have selected 10 biopharma companies with market caps under $3bn they think are primed for acquisition – and the likely candidates for a buy-out.

M & A StartUps and SMEs
See All

Company Information

  • Industry
  • Biotechnology
  • Medical Devices
  • Pharmaceuticals
    • Drug Delivery
      • Pulmonary
  • Therapeutic Areas
  • Inflammation
  • Respiratory, Pulmonary
  • Alias(es)
  • Isis Resources PLC
  • Rhinopharma
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • Verona Pharma PLC
  • Senior Management
  • David Zaccardelli, PharmD, Pres. & CEO
    Mark W Hahn, CFO
    Nina Church, Executive Dir., Global Clinical Dev.
    Nancy Herje, Sr. Dir., Clinical Operations
  • Contact Info
  • Verona Pharma PLC
    Phone: (44) (0)203 283 4200
    3 More London Riverside
    London, SE1 2RE
    UK
UsernamePublicRestriction

Register